| Dr Kaled Bazzi, MD | |
|
2799 W Grand Blvd, Department Of Internal Medicine, Detroit, MI 48202-2608 | |
| (313) 916-1828 | |
| Not Available |
| Full Name | Dr Kaled Bazzi |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 25 Years |
| Location | 2799 W Grand Blvd, Detroit, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073522744 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 4301082214 (Michigan) | Secondary |
| 207R00000X | Internal Medicine | 4301082214 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospices Of Henry Ford | Sterling heights, MI | Hospice |
| Henry Ford Wyandotte Hospital | Wyandotte, MI | Hospital |
| Henry Ford Hospital | Detroit, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Henry Ford Medical Group | 0547178311 | 2095 |
News Archive
Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2009.
Sesen Bio, Inc., a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018.
The world's first comprehensive, automated outbreak detection system which will monitor over 3,000 infections and is ready to run during Olympics 2012, was developed by a researcher at The Open University.
Researchers from the Harvard affiliated Hebrew SeniorLife Institute for Aging Research, in collaboration with scientists from Beth Israel Deaconess Medical Center, Harvard Medical School, and Brown University, have found increasing evidence that the level of delirium in post-surgical patients is associated with the level of later cognitive decline in those same patients.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.
› Verified 4 days ago
| Entity Name | Henry Ford Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134144801 PECOS PAC ID: 0547178311 Enrollment ID: O20031105000139 |
News Archive
Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2009.
Sesen Bio, Inc., a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018.
The world's first comprehensive, automated outbreak detection system which will monitor over 3,000 infections and is ready to run during Olympics 2012, was developed by a researcher at The Open University.
Researchers from the Harvard affiliated Hebrew SeniorLife Institute for Aging Research, in collaboration with scientists from Beth Israel Deaconess Medical Center, Harvard Medical School, and Brown University, have found increasing evidence that the level of delirium in post-surgical patients is associated with the level of later cognitive decline in those same patients.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.
› Verified 4 days ago
| Entity Name | Sound Inpatient Physicians-michigan Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639311996 PECOS PAC ID: 5395896849 Enrollment ID: O20090624000252 |
News Archive
Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2009.
Sesen Bio, Inc., a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018.
The world's first comprehensive, automated outbreak detection system which will monitor over 3,000 infections and is ready to run during Olympics 2012, was developed by a researcher at The Open University.
Researchers from the Harvard affiliated Hebrew SeniorLife Institute for Aging Research, in collaboration with scientists from Beth Israel Deaconess Medical Center, Harvard Medical School, and Brown University, have found increasing evidence that the level of delirium in post-surgical patients is associated with the level of later cognitive decline in those same patients.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.
› Verified 4 days ago
| Entity Name | Lakeland Medical Practices |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538397120 PECOS PAC ID: 1658427042 Enrollment ID: O20090928000216 |
News Archive
Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2009.
Sesen Bio, Inc., a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018.
The world's first comprehensive, automated outbreak detection system which will monitor over 3,000 infections and is ready to run during Olympics 2012, was developed by a researcher at The Open University.
Researchers from the Harvard affiliated Hebrew SeniorLife Institute for Aging Research, in collaboration with scientists from Beth Israel Deaconess Medical Center, Harvard Medical School, and Brown University, have found increasing evidence that the level of delirium in post-surgical patients is associated with the level of later cognitive decline in those same patients.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.
› Verified 4 days ago
| Entity Name | Hospitalist Medicine Physicians Of Michigan - Grand Blanc, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225673940 PECOS PAC ID: 7113356007 Enrollment ID: O20200327001389 |
News Archive
Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2009.
Sesen Bio, Inc., a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018.
The world's first comprehensive, automated outbreak detection system which will monitor over 3,000 infections and is ready to run during Olympics 2012, was developed by a researcher at The Open University.
Researchers from the Harvard affiliated Hebrew SeniorLife Institute for Aging Research, in collaboration with scientists from Beth Israel Deaconess Medical Center, Harvard Medical School, and Brown University, have found increasing evidence that the level of delirium in post-surgical patients is associated with the level of later cognitive decline in those same patients.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kaled Bazzi, MD 2799 W Grand Blvd, Department Of Internal Medicine, Detroit, MI 48202-2608 Ph: (313) 916-1828 | Dr Kaled Bazzi, MD 2799 W Grand Blvd, Department Of Internal Medicine, Detroit, MI 48202-2608 Ph: (313) 916-1828 |
News Archive
Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2009.
Sesen Bio, Inc., a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018.
The world's first comprehensive, automated outbreak detection system which will monitor over 3,000 infections and is ready to run during Olympics 2012, was developed by a researcher at The Open University.
Researchers from the Harvard affiliated Hebrew SeniorLife Institute for Aging Research, in collaboration with scientists from Beth Israel Deaconess Medical Center, Harvard Medical School, and Brown University, have found increasing evidence that the level of delirium in post-surgical patients is associated with the level of later cognitive decline in those same patients.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces that its partner, CardioNova, has accomplished first dosing of subjects for its Phase 1b clinical trial with AtheroNova's lead compound, AHRO-001.
› Verified 4 days ago
Dr. Saba Alan Francis, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 50 E Canfield St, Detroit, MI 48201 Phone: 313-745-4525 | |
Dr. Roopkiranjot Kahlon, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4201 Saint Antoine St, University Health Center 2e, Detroit, MI 48201 Phone: 313-745-4525 | |
Avi Cohen, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 313-916-2600 | |
Waleed Obaid, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6071 W Outer Dr, Detroit, MI 48235 Phone: 313-966-3250 | |
Lindsey Aurora, Internal Medicine Medicare: Medicare Enrolled Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 313-916-2600 | |
Alexander Garbarino, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 313-916-2600 | |
Maria Diab, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 800-653-6568 Fax: 313-876-1305 |